Use of FDG-PET Imaging for Patients With Disseminated Cancer of the Appendix

Am Surg. 2010 Dec;76(12):1338-44.

Abstract

The goal of this study is to evaluate the use of positron emission tomography (PET) in evaluation of patients with peritoneal dissemination of carcinoma of appendiceal origin (PDA). Thirty-three patients with PDA, who had preoperative PET or PET/CT imaging, were analyzed. Using operative, pathology, and PET +/- CT data, presence or absence of disease in each abdominal quadrant was noted and the use of 18fluoro-deoxy-glucose (FDG) PET for each quadrant was evaluated. The mean age was 52, and there were 17 males; 58 per cent had low-grade lesions. PET was positive in only 35 per cent of cases overall (30 and 41% sensitivity for low-grade and high-grade, respectively). PET without CT sensitivity for low-grade and high-grade lesions was 21 and 8 per cent, respectively. PET imaging has limited use for patients with PDA. We do not recommend the use of FDG-PET for patients with PDA from cancer of the appendix.

MeSH terms

  • Adenocarcinoma, Mucinous / diagnostic imaging*
  • Adenocarcinoma, Mucinous / mortality
  • Adenocarcinoma, Mucinous / pathology
  • Adult
  • Aged
  • Aged, 80 and over
  • Appendiceal Neoplasms / mortality
  • Appendiceal Neoplasms / pathology*
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Peritoneal Neoplasms / diagnostic imaging*
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / pathology
  • Positron-Emission Tomography*
  • Pseudomyxoma Peritonei / diagnostic imaging*
  • Pseudomyxoma Peritonei / mortality
  • Pseudomyxoma Peritonei / pathology
  • Radiopharmaceuticals
  • Survival Analysis

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18